The global prevalence of male hypogonadism or testosterone deficiency (TD) ranges from 2.1%-12.8% in men between the ages of 40-79 years and the incidence of low testosterone and symptoms in middle-aged men varies from 2.1%to 5.7%, according to the 2018 European Association of Urology (EAU) guideline.

Testosterone therapy has been shown to be effective but should be used with caution in some patients (those at high risk of CVD and prostate cancer).

Please sign in to read more